Is Ginkgo Bioworks Holdings Inc.’s (NYSE: DNA) -18.77% Loss This Week Telling Us Something New? – Marketing Sentinel
Home  »  Company   »  Is Ginkgo Bioworks Holdings Inc.’s (NYSE: DNA) -...

Is Ginkgo Bioworks Holdings Inc.’s (NYSE: DNA) -18.77% Loss This Week Telling Us Something New?

During the last session, Ginkgo Bioworks Holdings Inc. (NYSE:DNA)’s traded shares were 26.4 million. At the end of the trading day, the stock’s price was $2.38, reflecting an intraday gain of 8.18% or $0.18. The 52-week high for the DNA share is $15.86, that puts it down -566.39 from that peak though still a striking 8.4% gain since the share price plummeted to a 52-week low of $2.18. The company’s market capitalization is $3.83B, and the average intraday trading volume over the past 10 days was 23.14 million shares, and the average trade volume was 19.26 million shares over the past three months.

Ginkgo Bioworks Holdings Inc. (DNA) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 1.50. DNA has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.04.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Ginkgo Bioworks Holdings Inc. (NYSE:DNA) trade information

Ginkgo Bioworks Holdings Inc. (DNA) registered a 8.18% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 8.18% in intraday trading to $2.38 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -18.77%, and it has moved by -31.01% in 30 days. Based on these gigs, the overall price performance for the year is -75.91%. The short interest in Ginkgo Bioworks Holdings Inc. (NYSE:DNA) is 42.91 million shares and it means that shorts have 5.13 day(s) to cover.

The consensus price target of analysts on Wall Street is $8.75, which implies an increase of 72.8% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.00 and $12.00 respectively. As a result, DNA is trading at a discount of -404.2% off the target high and -152.1% off the low.

Ginkgo Bioworks Holdings Inc. (DNA) estimates and forecasts

Statistics show that Ginkgo Bioworks Holdings Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Ginkgo Bioworks Holdings Inc. (DNA) shares have gone down -82.53% during the last six months, with a year-to-date growth rate more than the industry average at 13.33% against -0.10.

Revenue for the current quarter is expected to be $55.25 million as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $59.8 million by the end of Mar 2022.

DNA Dividends

Ginkgo Bioworks Holdings Inc. is due to release its next quarterly earnings on November 15. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Ginkgo Bioworks Holdings Inc. (NYSE:DNA)’s Major holders

Ginkgo Bioworks Holdings Inc. insiders own 7.51% of total outstanding shares while institutional holders control 73.45%, with the float percentage being 79.41%. Viking Global Investors, L.P. is the largest shareholder of the company, while 148 institutions own stock in it. As of Sep 29, 2021, the company held over 302.94 million shares (or 23.11% of all shares), a total value of $3.51 billion in shares.

The next largest institutional holding, with 114.89 million shares, is of General Atlantic, L.P.’s that is approximately 8.76% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $1.33 billion.

Also, the Mutual Funds coming in first place with the largest holdings of Ginkgo Bioworks Holdings Inc. (DNA) shares are ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF. Data provided on Oct 30, 2021 indicates that ARK ETF Tr-ARK Innovation ETF owns about 19.82 million shares. This amounts to just over 1.51 percent of the company’s overall shares, with a $273.97 million market value. The same data shows that the other fund manager holds slightly less at 15.8 million, or about 1.21% of the stock, which is worth about $218.41 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts